Medicare, Medicaid, and HSA/FSA: The GLP-1 Rules the Federal Government Actually Sets

Most GLP-1 coverage confusion comes from treating "insurance" as one thing. Government coverage runs on statute, not on the same discretionary policy logic as a commercial plan, and the actual federal rule is more specific — and more consistently applied — than most coverage explainers let on.

The exclusion is written into federal law

This is the fact almost never stated plainly: federal law explicitly lists "agents when used for anorexia, weight loss, or weight gain" as a category of drugs that may be excluded from Medicaid's covered outpatient drug program¹. That single statutory line, 42 U.S.C. § 1396r-8(d)(2)(A), is the legal foundation both state Medicaid programs and — through cross-referencing provisions — traditional Medicare Part D formularies have relied on for years to exclude anti-obesity medications from routine coverage, regardless of a patient's individual medical necessity. This isn't an insurer being stingy; it's a specific category Congress wrote into the statute governing what these programs have to cover.

Three real, narrow exceptions — not workarounds, actual law

The exclusion is real, but it isn't absolute, and conflating "generally excluded" with "never covered" is the most common mistake people make researching this.

The first exception is state discretion under Medicaid: the statute frames weight-loss agents as drugs that "may be excluded," which means individual state Medicaid programs retain the option to cover them anyway, and coverage genuinely varies state by state as a result — check your specific state Medicaid formulary rather than assuming exclusion is universal.

The second is EPSDT. A federal Medicaid provision called Early and Periodic Screening, Diagnostic, and Treatment requires state Medicaid programs to cover medically necessary services for people under 21, even services outside the state's standard benefit list — a lever specifically documented for obtaining obesity pharmacotherapy coverage for eligible youth, and one clinicians report is underused mainly because families and even prescribers don't know to invoke it².

The third is federal employee coverage: Federal Employees Health Benefits Program carriers are required by an Office of Personnel Management mandate to offer adequate coverage of FDA-approved anti-obesity medications³ — a real, concrete instance of coverage being mandated rather than merely permitted, worth knowing if you or a family member has FEHB coverage. None of these three exceptions apply universally, and none guarantee your specific situation is covered — see our full breakdown of how GLP-1 prior authorization works in practice for what a plan actually checks once you clear the initial exclusion question.

The HSA/FSA angle almost nobody uses correctly

Separate from insurance coverage entirely, there's a tax-code lever worth understanding: the IRS has long held, in Revenue Ruling 2002-19, that obesity is a disease in its own right, and that uncompensated amounts paid to treat a physician-diagnosed disease — including obesity — qualify as deductible medical care expenses⁴. That ruling is the same legal basis that makes a physician-diagnosed, obesity-related GLP-1 prescription an eligible expense under most HSA and FSA plans, separate from whether your insurance itself covers the drug. If your plan denies the prescription outright, paying cash and running it through an HSA or FSA — where your employer's specific plan document allows it — is a real, legally grounded way to capture pre-tax savings on a cash-pay GLP-1, worth confirming with your plan administrator before you assume it isn't an option.

What to actually do with this

Start by checking your specific coverage type against the right category: state Medicaid formulary if you're on Medicaid, your specific Medicare Part D plan's formulary if traditional Medicare, and FEHB status if you're a federal employee. If none of those apply or none cover your prescription, price the cash-pay routes — what a GLP-1 costs without insurance and true monthly cost beyond the sticker price — and ask your HSA or FSA administrator directly whether a physician-diagnosed obesity prescription qualifies under Revenue Ruling 2002-19 before writing off the pre-tax savings. The statutory and regulatory sources behind this article are indexed in our research library. Not medical advice, and not tax advice — see our medical disclaimer and confirm your specific plan's rules with your benefits administrator, Medicaid caseworker, or a tax professional.